{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T20:03:30Z","timestamp":1792181010719,"version":"4.4.0"},"reference-count":37,"publisher":"American Medical Association (AMA)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Ophthalmol"],"published-print":{"date-parts":[[2021,1,1]]},"DOI":"10.1001\/jamaophthalmol.2020.5053","type":"journal-article","created":{"date-parts":[[2020,11,19]],"date-time":"2020-11-19T17:56:43Z","timestamp":1605808603000},"page":"68","source":"Crossref","is-referenced-by-count":86,"title":["Efficacy and Safety of a Proposed Ranibizumab Biosimilar Product vs a Reference Ranibizumab Product for Patients With Neovascular Age-Related Macular Degeneration"],"prefix":"10.1001","volume":"139","author":[{"given":"Se Joon","family":"Woo","sequence":"first","affiliation":[{"name":"Department of Ophthalmology, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miroslav","family":"Veith","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Third Faculty of Medicine, Charles University in Prague, Prague, Czech Republic"},{"name":"Department of Ophthalmology, University Hospital Kralovske Vinohrady, Prague, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Hamouz","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Third Faculty of Medicine, Charles University in Prague, Prague, Czech Republic"},{"name":"Department of Ophthalmology, University Hospital Kralovske Vinohrady, Prague, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Ernest","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Central Military Hospital, Prague, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominik","family":"Zalewski","sequence":"additional","affiliation":[{"name":"Diagnostic and Microsurgery Center of the Eye LENS, Olsztyn, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Studnicka","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Faculty of Medicine in Hradec Kralove, Charles University in Prague, Prague, Czech Republic"},{"name":"Department of Ophthalmology, University Hospital Hradec Kralove, Hradec Kralove, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Attila","family":"Vajas","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, University of Debrecen, Debrecen, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andras","family":"Papp","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Semmelweis University, Budapest, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vogt","family":"Gabor","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Medical Centre, Hungarian Defence Forces, Budapest, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Luu","sequence":"additional","affiliation":[{"name":"Retina Consultants of Southern Colorado, Colorado Springs"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronika","family":"Matuskova","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, University Hospital Brno, Brno, Czech Republic"},{"name":"Faculty of Medicine Masaryk University, Brno, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Young Hee","family":"Yoon","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tam\u00e1s","family":"Pregun","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Bajcsy-Zsilinszky Hospital, Budapest, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taehyung","family":"Kim","sequence":"additional","affiliation":[{"name":"Medical Team, Samsung Bioepis, Incheon, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donghoon","family":"Shin","sequence":"additional","affiliation":[{"name":"Medical Team, Samsung Bioepis, Incheon, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil M.","family":"Bressler","sequence":"additional","affiliation":[{"name":"Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland"},{"name":"Editor, JAMA Ophthalmology"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"key":"eoi200092r1","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1159\/issn.0250-3751","article-title":"Neovascular age-related macular degeneration.","volume":"55","author":"Shao","year":"2016","journal-title":"Dev Ophthalmol"},{"issue":"4","key":"eoi200092r2","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1016\/j.preteyeres.2008.05.002","article-title":"The role of vascular endothelial growth factor and other endogenous interplayers in age-related macular degeneration.","volume":"27","author":"Grisanti","year":"2008","journal-title":"Prog Retin Eye Res"},{"issue":"10153","key":"eoi200092r3","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1016\/S0140-6736(18)31550-2","article-title":"Age-related macular degeneration.","volume":"392","author":"Mitchell","year":"2018","journal-title":"Lancet"},{"issue":"3","key":"eoi200092r4","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1080\/14728214.2017.1362390","article-title":"Emerging vascular endothelial growth factor antagonists to treat neovascular age-related macular degeneration.","volume":"22","author":"Hussain","year":"2017","journal-title":"Expert Opin Emerg Drugs"},{"issue":"1","key":"eoi200092r5","doi-asserted-by":"publisher","first-page":"27","DOI":"10.4103\/0974-9233.173133","article-title":"Management of neovascular age-related macular degeneration: a review on landmark randomized controlled trials.","volume":"23","author":"Agarwal","year":"2016","journal-title":"Middle East Afr J Ophthalmol"},{"issue":"1","key":"eoi200092r6","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.ophtha.2018.07.028","article-title":"Safety and efficacy of anti-vascular endothelial growth factor therapies for neovascular age-related macular degeneration: a report by the American Academy of Ophthalmology.","volume":"126","author":"Bakri","year":"2019","journal-title":"Ophthalmology"},{"key":"eoi200092r7","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.12688\/f1000research","article-title":"Emerging therapies in the management of macular edema: a review.","volume":"8","author":"Sacconi","year":"2019","journal-title":"F1000Res"},{"issue":"10153","key":"eoi200092r10","first-page":"1090","article-title":"Age-related macular degeneration: treatment at what cost?","volume":"392","author":"The Lancet","year":"2018","journal-title":"Lancet"},{"key":"eoi200092r11","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.drudis.2015.03.011","article-title":"Key considerations in the preclinical development of biosimilars.","volume":"20","author":"Bui","year":"2015","journal-title":"Drug Discov Today"},{"issue":"6","key":"eoi200092r12","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1185\/03007995.2012.686902","article-title":"Comparability and biosimilarity: considerations for the healthcare provider.","volume":"28","author":"Lee","year":"2012","journal-title":"Curr Med Res Opin"},{"issue":"20","key":"eoi200092r18","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1001\/jama.2013.281053","article-title":"World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects.","volume":"310","author":"World Medical Association","year":"2013","journal-title":"JAMA"},{"issue":"5","key":"eoi200092r20","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/j.biologicals.2015.06.004","article-title":"Immunogenicity assessment of biotherapeutic products: an overview of assays and their utility.","volume":"43","author":"Wadhwa","year":"2015","journal-title":"Biologicals"},{"issue":"14","key":"eoi200092r21","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1056\/NEJMoa054481","article-title":"Ranibizumab for neovascular age-related macular degeneration.","volume":"355","author":"Rosenfeld","year":"2006","journal-title":"N Engl J Med"},{"issue":"5","key":"eoi200092r22","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1016\/j.ajo.2007.12.029","article-title":"Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration (FOCUS): year 2 results.","volume":"145","author":"Antoszyk","year":"2008","journal-title":"Am J Ophthalmol"},{"issue":"2","key":"eoi200092r23","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/j.ajo.2007.10.004","article-title":"Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1.","volume":"145","author":"Regillo","year":"2008","journal-title":"Am J Ophthalmol"},{"issue":"1","key":"eoi200092r24","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.ophtha.2008.10.018","article-title":"Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of the ANCHOR Study.","volume":"116","author":"Brown","year":"2009","journal-title":"Ophthalmology"},{"issue":"4","key":"eoi200092r26","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1016\/j.ajo.2007.01.028","article-title":"An optical coherence tomography\u2013guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration.","volume":"143","author":"Fung","year":"2007","journal-title":"Am J Ophthalmol"},{"issue":"1","key":"eoi200092r27","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.ajo.2009.01.024","article-title":"A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO Study.","volume":"148","author":"Lalwani","year":"2009","journal-title":"Am J Ophthalmol"},{"issue":"20","key":"eoi200092r28","doi-asserted-by":"publisher","first-page":"1897","DOI":"10.1056\/NEJMoa1102673","article-title":"Ranibizumab and bevacizumab for neovascular age-related macular degeneration.","volume":"364","author":"Martin","year":"2011","journal-title":"N Engl J Med"},{"issue":"5","key":"eoi200092r29","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1016\/j.ophtha.2012.10.014","article-title":"Twelve-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration.","volume":"120","author":"Busbee","year":"2013","journal-title":"Ophthalmology"},{"issue":"9","key":"eoi200092r30","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1136\/bjophthalmol-2013-303232","article-title":"Safety of ranibizumab in routine clinical practice: 1-year retrospective pooled analysis of four European neovascular AMD registries within the LUMINOUS programme.","volume":"97","author":"Holz","year":"2013","journal-title":"Br J Ophthalmol"},{"issue":"2","key":"eoi200092r31","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1038\/eye.2015.217","article-title":"Ranibizumab for the treatment of wet AMD: a summary of real-world studies.","volume":"30","author":"Chong","year":"2016","journal-title":"Eye (Lond)"},{"issue":"9","key":"eoi200092r32","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1097\/IAE.0000000000002670","article-title":"Ranibizumab treatment in treatment-naive neovascular age-related macular degeneration: results from LUMINOUS, a global real-world study.","volume":"40","author":"Holz","year":"2020","journal-title":"Retina"},{"issue":"2","key":"eoi200092r33","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1136\/bjophthalmol-2014-305327","article-title":"Multi-country real-life experience of anti-vascular endothelial growth factor therapy for wet age-related macular degeneration.","volume":"99","author":"Holz","year":"2015","journal-title":"Br J Ophthalmol"},{"key":"eoi200092r34","doi-asserted-by":"publisher","first-page":"2137","DOI":"10.2147\/OPTH","article-title":"Biosimilars in ophthalmology: \u201cis there a big change on the horizon?\u201d","volume":"12","author":"Sharma","year":"2018","journal-title":"Clin Ophthalmol"},{"issue":"2","key":"eoi200092r36","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1007\/s40259-019-00395-w","article-title":"Identifying key benefits in European off-patent biologics and biosimilar markets: it is not only about price!","volume":"34","author":"Dutta","year":"2020","journal-title":"BioDrugs"},{"issue":"1","key":"eoi200092r37","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1007\/s00228-019-02765-3","article-title":"The Danish model for the quick and safe implementation of infliximab and etanercept biosimilars.","volume":"76","author":"Jensen","year":"2020","journal-title":"Eur J Clin Pharmacol"},{"key":"eoi200092r8","unstructured":"US Food and Drug Administration. Drugs@FDA: FDA-approved drugs: Lucentis. Accessed March 24, 2020. https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm?event=overview.process&ApplNo=125156"},{"key":"eoi200092r9","unstructured":"European Medicines Agency. Lucentis. Accessed March 24, 2020. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/lucentis#authorisation-details-section"},{"key":"eoi200092r13","unstructured":"European Medicines Agency. Guideline on similar biological medicinal products. Published October 23, 2014. Accessed March 24, 2020. https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-similar-biological-medicinal-products-rev1_en.pdf"},{"key":"eoi200092r14","unstructured":"US Food and Drug Administration. Scientific considerations in demonstrating biosimilarity to a reference product: guidance for industry. Published April 2015. Accessed March 24, 2020. https:\/\/www.fda.gov\/media\/82647\/download"},{"key":"eoi200092r15","unstructured":"European Medicines Agency. Biosimilars in the EU: information guide for healthcare professionals. Updated February 10, 2019. Accessed March 24, 2020. https:\/\/www.ema.europa.eu\/en\/documents\/leaflet\/biosimilars-eu-information-guide-healthcare-professionals_en.pdf"},{"key":"eoi200092r16","unstructured":"US Food and Drug Administration. Biosimilar development, review, and approval. Updated October 20, 2017. Accessed March 24, 2020. https:\/\/www.fda.gov\/drugs\/biosimilars\/biosimilar-development-review-and-approval"},{"key":"eoi200092r17","unstructured":"US Food and Drug Administration. Biosimilar and interchangeable products. Updated October 23, 2017. Accessed August 31, 2020. https:\/\/www.fda.gov\/drugs\/biosimilars\/biosimilar-and-interchangeable-products"},{"key":"eoi200092r19","unstructured":"MedDRA. What\u2019s new: MedDRA version 20.1. Published September 2017. Accessed October 18, 2020. https:\/\/admin.new.meddra.org\/sites\/default\/files\/guidance\/file\/whatsnew_20_1_english.pdf"},{"key":"eoi200092r25","unstructured":"Lucentis. Prescribing information. Genentech. Updated March 2018. Accessed April 2, 2020. https:\/\/www.gene.com\/download\/pdf\/lucentis_prescribing.pdf"},{"key":"eoi200092r35","unstructured":"European Federation of Pharmaceutical Industries and Associations. Promoting safe and effective biosimilars can lead to more affordable biologic medicines. Published 2016. Accessed March 24, 2020. https:\/\/www.efpia.eu\/publications\/data-center\/medicines-costs-in-context\/biosimilars\/"}],"container-title":["JAMA Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaophthalmology\/articlepdf\/2772987\/jamaophthalmology_woo_2020_oi_200092_1610718713.62793.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,20]],"date-time":"2021-01-20T16:01:49Z","timestamp":1611158509000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaophthalmology\/fullarticle\/2772987"}},"subtitle":["A Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2021,1,1]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,1,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaophthalmol.2020.5053","relation":{},"ISSN":["2168-6165"],"issn-type":[{"value":"2168-6165","type":"print"}],"subject":[],"published":{"date-parts":[[2021,1,1]]}}}